Why Optellum’s deployment at Tanner Health could matter for lung cancer risk stratification
Find out how Tanner Health’s Optellum rollout could reshape AI lung nodule triage and early lung cancer detection in regional care.
Medical Devices & Diagnostics
Pharma & Biotech
Could DermaSensor’s NHS study turn AI skin cancer tools into primary care infrastructure?
Find out how DermaSensor’s CE Mark and NHS study could reshape AI-assisted skin cancer assessment across European primary care.
Medical Devices & Diagnostics
Can SOPHiA GENETICS and Memorial Sloan Kettering turn oncology data into a precision medicine engine?
SOPHiA GENETICS and Memorial Sloan Kettering aim to turn cancer data into precision oncology infrastructure. Can the hub deliver?
Medical Devices & Diagnostics
How Philips’ Elevate Plus could change abdominal, breast and thyroid ultrasound workflows
Philips’ Elevate Plus puts AI inside ultrasound workflows. The real test is whether hospitals see faster scans and fewer repeat exams.
Medical Devices & Diagnostics
FDA breakthrough status gives Coredio’s AI heart failure platform a faster regulatory path
Coredio’s AI heart failure platform may bring hemodynamic insight into home care. See why FDA breakthrough status matters now.
Pharma & Biotech
Can AI help Biomunex find better bispecific antibody targets in cancer?
AI may speed cancer drug discovery, but Biomunex’s bigger test is whether smarter target pairing can translate into stronger immunotherapies.
Features & Analysis
Drug discovery has an AI problem. Clicklinks thinks the answer is connection, not just algorithms
Find out how Sanyou Bio’s Clicklinks platform could reshape AI-led drug discovery by linking biotech, CRO, CDMO and preclinical resources.
Pharma & Biotech
Can Anthropic’s Claude help Bristol Myers Squibb speed up medicine discovery and delivery?
Bristol Myers Squibb is moving AI from pilots to enterprise scale. Claude’s real test is governance, data trust and drug development impact.
Medical Devices & Diagnostics
Can ArteraAI Breast turn routine pathology slides into breast cancer risk intelligence?
AI can read pathology slides, but can it change breast cancer treatment decisions? ArteraAI Breast puts that question before clinicians and payers.
Features & Analysis
Are autonomous labs quietly turning biopharma researchers into scientific strategists?
Autonomous labs can run experiments faster. The bigger shift is what happens when biopharma researchers stop executing and start directing.